BiotechTube

TERN-501 + TERN-101

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH - Nonalcoholic Steatohepatitis

Conditions

NASH - Nonalcoholic Steatohepatitis

Trial Timeline

Jun 28, 2022 → Jul 10, 2023

NCT ID
NCT05415722

About TERN-501 + TERN-101

TERN-501 + TERN-101 is a phase 2 stage product being developed by Terns Pharmaceuticals for NASH - Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05415722. Target conditions include NASH - Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05415722Phase 2Completed

Competing Products

20 competing products in NASH - Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
AZD2693AstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
Tropifexor + LicogliflozinNovartisPhase 2
52
LMB763 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + PlaceboNovartisPhase 2
52
TRO19622 + PlaceboRochePhase 2
52
SEL + SIMGilead SciencesPhase 2
51
Seladelpar + PlacebosGilead SciencesPhase 2
51
Placebo + SIMGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
51

Other Products from Terns Pharmaceuticals

TERN-101Phase 2
49
TERN-601Phase 2
49
TERN-701Phase 1/2
38
TERN-201Phase 1
30